Monograph
N05AD01 - Haloperidol |
Propably not porphyrinogenic |
PNP |
Rationale
No data pointing to CYP-induction. Repeatedly used in acute porphyria without ill effects. Several references state non-porphyrinogenicity.
Chemical description
Butyrphenone low-dose neuroleptic used in psychotic conditions (e.g.in paranoia), also in childhood. Used in confusion states in elderly and against vomiting, e.g. in radiation sickness. Extensively metabolized, CYPs probably involved. No data pointing to CYP-inducing properties. Australian list: safe (conflicting evidence) EPI-list: safe South African list: use French list: use Martindale: Haloperidol is considered to be safe in patients with porphyria although there is conflicting experimental evidence of porphyrinogenicity.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
